证券代码：002412 证券简称：汉森制药 公告编号：2025-029 湖南汉森制药股份有限公司 关于取得换发《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 湖南汉森制药股份有限公司（以下简称"公司"）近日收到湖南省药品监督管理 局换发的《药品生产许可证》，换发后的《药品生产许可证》的有效期至 2030 年 11 月 06 日，现将有关情况公告如下： 一、新的《药品生产许可证》基本信息 企业名称：湖南汉森制药股份有限公司 法定代表人：刘正清 企业负责人：刘正清 质量负责人：刘爱华 有效期至：2030 年 11 月 06 日 生产地址和生产范围：益阳市赫山区银城大道 2688 号：大容量注射剂、小容量 注射剂、片剂、硬胶囊剂、颗粒剂、糖浆剂、酊剂、合剂、丸剂（蜜丸、水蜜丸、水 丸）、煎膏剂（含中药前处理及提取）、第二类精神药品（氢溴酸右美沙芬颗粒）*** 二、对公司影响及风险提示 许可证编号：湘 20150132 社会信用代码：91430900MA4L101B51 分类码：Ahz 注册地址：益阳市赫山区银城大道 2688 号 本次换发《 ...

Core Viewpoint - Hansen Pharmaceutical has a range of products for treating colds, including Ganmao Qingre Granules, Baibei Yilung Capsules, Compound Acetaminophen and Amantadine Tablets, and Huoxiang Zhengqi Liquid [2] Company Summary - Hansen Pharmaceutical, including its wholly-owned subsidiaries, offers various cold treatment products [2]

Meeting Overview - The first extraordinary general meeting of shareholders for Hunan Hansen Pharmaceutical Co., Ltd. was held on November 13, 2025, combining on-site voting and online voting [4][5][6] - A total of 102 shareholders and their authorized representatives attended the meeting, representing 221,226,929 shares with voting rights, accounting for 43.9640% of the total voting shares [7] Resolutions Passed - The meeting approved several proposals, including amendments to the company's articles of association and various management systems [10] - Specific proposals that received approval include revisions to the rules for shareholder meetings, board meetings, independent director work systems, related party transaction management, external guarantee management, external investment management, dividend management, and fundraising usage management [10] Legal Compliance - The meeting's procedures, including the qualifications of the conveners and attendees, voting procedures, and results, were confirmed to be in compliance with the Company Law and other relevant regulations [12] Election of Employee Representative Director - The fourth second employee representative meeting elected Ms. Hu Qiong as the employee representative director for the sixth board of directors, with her term lasting until the board's term ends [13] - Ms. Hu Qiong's election complies with regulations regarding the composition of the board, ensuring that the number of employee representatives does not exceed half of the total board members [13]

Group 1 - The company announced the convening of the fourth second employee representative assembly on November 13, 2025 [1] - During the assembly, employee representatives elected Ms. Hu Qiong as the employee representative director of the sixth board of directors [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 湖南汉森制药股份有限公司（以下简称"公司"）根据《中华人民共和国公 司法》《上市公司章程指引》及《关于新<公司法>配套制度规则实施相关过渡 期安排》的相关规定，于2025年11月13日在公司一楼大会议室召开第四届第二 次职工代表大会，经与会职工代表认真审议，同意选举胡琼女士为公司第六届董 事会职工代表董事，任期至第六届董事会届满。胡琼女士简历详见附件。 胡琼女士当选公司职工代表董事后，公司董事会中兼任高级管理人员以及由 职工代表担任的董事人数总计不超过公司董事总数的二分之一，符合相关法律法 规及规范性文件的规定。 湖南汉森制药股份有限公司 证券代码：002412 证券简称：汉森制药 公告编号：2025-028 湖南汉森制药股份有限公司 关于选举职工代表董事的公告 - 2 - 董事会 2025年11月14日 - 1 - 附件： 职工代表董事简历 胡琼，女，中国国籍，无境外永久居留权，1974年9月出生，本科学历，高 级人力资源管理师。曾任湖南汉森制药有限公司办公室副主任、人力资源部部长， 湖南汉森制药股份有限公司 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-027 湖南汉森制药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示 1．本次股东大会未出现否决提案的情形。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 4．会议召集人：公司董事会 2025 年 10 月 24 日召开的第六届董事会第九次会议决定召开本次股东大会。 5．会议主持人：公司董事长兼总裁刘正清先生 6．本次股东大会的召集、召开程序符合《公司法》《上市公司股东会规则》等 法律法规、规范性文件以及《公司章程》的规定。 （二）股东出席会议情况 出席本次股东大会的股东及股东授权委托代表人共 102 人，代表有表决权的股份 数为 221,226,929 股，占公司有表决权总股份的 43.9640%。其中： 1．会议召开时间 （1）现场会议时间：2025 年 11 月 13 日（星期四）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 ...

湖南启元律师事务所 HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号 世茂环球金融中心 63 层 410000 Tel：(0731) 8295 3778 Fax：(0731) 8295 3779 http://www.qiyuan.com 湖南启元律师事务所 关于湖南汉森制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：湖南汉森制药股份有限公司 本所律师声明如下： （一）本所律师根据本法律意见书出具日以前已经发生或者存在的事实，严 格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证， 保证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准 确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 （二）本所律师出具本法律意见是基于公司已承诺所有提供给本所律师的文 件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠，无 隐瞒、虚假或重大遗漏之处。 （三）本所律师未授权任何单位或个人对本法律意见书作任何解释或说明。 鉴此，本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神， 就本次股东大会发表法律意 ...

Group 1 - The core point of the article is that Hansen Pharmaceutical reported a total of 23,941 shareholders as of October 31, 2025, including those in credit accounts [2]

Group 1 - The company, Hansen Pharmaceutical, reaffirmed its commitment to traditional Chinese medicine as its core business during a recent interaction with investors [2] - The company aims to provide stable and continuous operating performance to return value to its investors [2]

Company Overview - Hansen Pharmaceutical was established on January 21, 1998, and listed on the Shenzhen Stock Exchange on May 25, 2010. The company is based in Yiyang, Hunan Province, and is a well-known pharmaceutical enterprise in China, focusing on the research and development of traditional Chinese medicine, with its core product, Simiao Decoction Oral Liquid, leading the market share [1] Financial Performance - In the third quarter of 2025, Hansen Pharmaceutical achieved a revenue of 741 million yuan, ranking 47th among 69 industry companies. The industry leader, Baiyunshan, reported a revenue of 61.606 billion yuan, while the second, Yunnan Baiyao, reported 30.654 billion yuan. The industry average revenue was 3.755 billion yuan, with a median of 1.462 billion yuan [2] - The company's net profit for the same period was 82.5252 million yuan, ranking 36th in the industry. The top performer, Yunnan Baiyao, had a net profit of 4.789 billion yuan, and Baiyunshan followed with 3.398 billion yuan. The industry average net profit was 447 million yuan, with a median of 83.6773 million yuan [2] Financial Ratios - Hansen Pharmaceutical's debt-to-asset ratio was 11.77% in the third quarter of 2025, down from 14.33% in the previous year and significantly lower than the industry average of 32.81%. The company's gross profit margin was 77.04%, an increase from 75.13% year-on-year and higher than the industry average of 52.44% [3] Executive Compensation - The chairman and president, Liu Zhengqing, received a salary of 1.7064 million yuan in 2024, an increase of 30,700 yuan from 2023. Liu Zhengqing has a master's degree and has held various positions, including workshop director at Yiyang Pharmaceutical Factory [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders of Hansen Pharmaceutical was 23,300, a decrease of 1.20% from the previous period. The average number of circulating A-shares held per shareholder increased by 1.21% to 21,400 shares. Among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) was the eighth largest, holding 2.114 million shares as a new shareholder [5]